Last reviewed · How we verify
Estradiol (E2 0.3mg)
Estradiol is a naturally occurring estrogen that binds to estrogen receptors (ERα and ERβ) to modulate hormone-dependent physiological processes.
Estradiol is a naturally occurring estrogen that binds to estrogen receptors (ERα and ERβ) to modulate hormone-dependent physiological processes. Used for Menopausal vasomotor symptoms (hot flashes, night sweats), Postmenopausal osteoporosis prevention, Estrogen deficiency states.
At a glance
| Generic name | Estradiol (E2 0.3mg) |
|---|---|
| Sponsor | Bayer |
| Drug class | Estrogen receptor agonist |
| Target | Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | Phase 3 |
Mechanism of action
Estradiol is the most potent endogenous estrogen and acts as a ligand for nuclear estrogen receptors, regulating gene transcription involved in reproductive, cardiovascular, bone, and central nervous system function. The 0.3 mg dose formulation is typically used for hormone replacement therapy or treatment of estrogen deficiency states. Bayer's phase 3 program likely evaluates efficacy and safety in menopausal symptoms or bone health indications.
Approved indications
- Menopausal vasomotor symptoms (hot flashes, night sweats)
- Postmenopausal osteoporosis prevention
- Estrogen deficiency states
Common side effects
- Breast tenderness
- Headache
- Nausea
- Vaginal bleeding/spotting
- Fluid retention
- Thromboembolic events
Key clinical trials
- Regulation of Cervical Mucus Secretion (PHASE4)
- Low-dose Hormone Therapy for Relief of Vasomotor Symptoms (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |